Post COVID syndrome, neurological and psychiatric sequels.
Article Sidebar
Main Article Content
Abstract
COVID-19 disease is the product of the infection by the type 2 Coronavirus that causes a severe acute respiratory syndrome (SARS-COV-2). It originated the pandemic during 2020-2023. Patients infected by COVID-19 can remain asymptomatic or develop mild respiratory symptoms or even multisystemic failure. Some of the most common symptoms are fever, cough, headache, anosmia, and sore throat. Post COVID syndrome is defined by the persistence of signs and symptoms that arise during or after suffering from COVID-19, remain for more than 12 weeks and are not explained by another cause. The most common neuropsychiatric sequelae are fatigue, confusion, memory and attention disorders, myalgia, anosmia, headache, anxiety and depression. Neuropsychiatric symptoms may be due to viral invasion of the nervous system, inflammatory states or alteration of the immune system. The objective of this review lies in the identification of neurological sequelae that may go unnoticed in patients with a history of COVID-19.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
References
1. Loscalzo J, Kasper DL, Longo DL, Fauci AS, Hauser SL, Jameson J (Ed). Harrison Principios de Medicina Interna. Edición 21. McGraw Hill; 2022. 1508-1511.
2. Carod-Artal FJ. Síndrome post-COVID-19: epidemiología, criterios diagnósticos y mecanismos patogénicos implicados. Rev Neurol. 2021;72:384-96.
3. Oficina de Rendición de Cuentas del Gobierno de los Estados Unidos. Science & Tech Spotlight: Long COVID. 2020. Disponible en: Science & Tech Spotlight: Long COVID | GAO DE LOS ESTADOS UNIDOS.
4. WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data.
5. Ministerio de Salud de Panamá. CORONAVIRUS COVID-19 | Ministerio de Salud de la República de Panamá (minsa.gob.pa).
6. Alkodaymi MS, Omrani OA, Fawzy NA. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:657-66.
7. Papineau A, Bibi L, Broce A, Elcock E, Mariscal R, Rodríguez J, et al. Manifestaciones clínicas en post COVID en adultos en la República de Panamá. Respirar. 2022;14:215-21.
8. Arcia D, Gómez L, Ng R, Velásquez LF. Prevalencia del diagnóstico Post-COVID en el Centro Integral de Atención Provisional (Figali) durante el primer trimestre de 2021. Rev. méd. Panamá. 2022;42:18-22.
9. Leng A, Shah M, Ahmad SA, Premraj L, Wildi K, Li Bassi G, et al. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12:816.
10. Mainous AG 3rd, Rooks BJ, Wu V, Orlando FA. COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk. Front Med (Lausanne). 2021 Dec 1;8:778434.
11. Meza-Torres B, Delanerolle G, Okusi C, Mayor N, Anand S, Macartney J, et al. Diferencias en la presentación clínica con COVID prolongado después de la infección comunitaria y hospitalaria y asociaciones con la mortalidad por todas las causas: estudio de base de datos de la red English Sentinel. JMIR Salud Pública Surveill. 2022;8:E37668.
12. Gao P, Liu J, Liu M. Efecto de las vacunas COVID-19 en la reducción del riesgo de COVID prolongado en el mundo real: una revisión sistemática y metanálisis. Int J Medio Ambiente Salud Pública. 2022;19:12422.
13. Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. El impacto de la vacunación COVID en los síntomas de COVID largo: una encuesta internacional de personas con experiencia vivida de COVID prolongado. Vacunas (Basilea). 2022;10:652.
14. Premraj L, Kannapadi NV, Briggs J. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J Neurol Sci. 2022;434:120162.
15. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220-32.
16. Rass V, Beer R, Schiefecker AJ, Lindner A, Kofler M, Ianosi BA, et al. Neurological outcomes 1 year after COVID-19 diagnosis: A prospective longitudinal cohort study. Eur J Neurol. 2022;29:1685-96.
17. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022;101:93-135.
18. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138-47.
19. Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110:3484-96.
20. Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA Netw Open. 2021;4:e2130645.
21. Estiri H, Strasser ZH, Brat GA, Semenov YR, Consortium for Characterization of COVID-19 by EHR (4CE), Patel CJ, et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med. 2021;19:249.
22. Iosifescu AL, Hoogenboom WS, Buczek AJ, Fleysher R, Duong TQ. New-onset and persistent neurological and psychiatric sequelae of COVID-19 compared to influenza: A retrospective cohort study in a large New York City healthcare network. Int J Methods Psychiatr Res. 2022;31:e1914.
23. Matar-Khalil S. Neurocovid-19: efectos del COVID-19 en el cerebro. Rev Panam Salud Publica. 2022;46:e108.
24. Bakhshandeh B, Sorboni SG, Javanmard AR, Mottaghi SS, Mehrabi MR, Sorouri F, et al. Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect Genet Evol. 2021;90:104773.
25. Leng A, Shah M, Ahmad SA, Premraj L, Wildi K, Li Bassi G, et al. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12:816.
26. Vaira LA, Hopkins C, Sandison A, Manca A, Machouchas N, Turilli D, et al. Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. J Laryngol Otol. 2020;134:1123-7.
27. Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210-6.
28. Arun S, Storan A, Myers B. Mast cell activation syndrome and the link with long COVID. Br J Hosp Med (Lond). 2022;83:1-10.
29. Samudyata, Oliveira AO, Malwade S, Rufino de Sousa N, Goparaju SK, Gracias J, et al. SARS-CoV-2 promotes microglial synapse elimination in human brain organoids. Mol Psychiatry. 2022;27:3939-50.
30. Woodruff MC, Walker TA, Truong AD, Dixit AN, Han JE, Ramonell RP, et al. Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection. medRxiv 2021. https://www.medrxiv.org/content/10.1101/2021.09.21.21263845v1.
31. Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.
32. Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:172.
33. Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12:eabd3876.
34. Christensen RH, Berg RMG. Vascular Inflammation as a Therapeutic Target in COVID-19 "Long Haulers": HIITing the Spot? Front Cardiovasc Med. 2021 Mar 19;8:643626.
35. Lee MH, Perl DP, Steiner J, Pasternack N, Li W, Maric D, et al. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022;145:2555-68.
36. Okrzeja J, Garkowski A, Kubas B, Moniuszko-Malinowska A. Imaging and neuropathological findings in patients with Post COVID-19 Neurological Syndrome—A review. Frontiers in Neurology. 2023;14:1136348.